https://www.biopharmadive.com/news/calquence-approval-boosts-astrazeneca-imbruvica-cll/567908/
The new FDA approval expands Calquence's use into a more common blood cancer, although doctors have already been prescribing it for that disease.
calquenceokboostsastrazenecachallenge
https://www.benzinga.com/general/biotech/21/06/21545497/jnjs-imbruvica-abbvies-venclexta-combo-achieves-progression-free-survival-of-78-4-versus-gazyva-c
jnjimbruvicaabbvievenclextacombo